<DOC>
	<DOCNO>NCT00542893</DOCNO>
	<brief_summary>This clinical drug-drug interaction study conduct evaluate pharmacokinetics dacarbazine ( DTIC ) administer combination Genasense</brief_summary>
	<brief_title>A Phase I , Randomized , Open-label , Cross-over , Pharmacokinetic Study Genasense With Without Dacarbazine</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Metastatic Stage IV disease , Stage III disease surgically resectable ECOG Performance Status 0 , 1 , 2 Life expectancy least 12 week Adequate venous access Agreement practice effective method birth control Less 3 week recovery prior major surgery therapy , include radiation therapy , chemotherapy , immunotherapy , cytokine , biologic , vaccine therapy Significant medical disease Known hypersensitivity phosphorothioatecontaining oligonucleotides Known hypersensitivity DTIC Pregnancy/Lactation</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>bcl-2</keyword>
	<keyword>CFR</keyword>
	<keyword>DTIC</keyword>
	<keyword>ECOG</keyword>
	<keyword>EMEA</keyword>
	<keyword>MedDRA</keyword>
	<keyword>NCI CTC</keyword>
	<keyword>SAE</keyword>
</DOC>